PD is a multifactorial disease and several risk factors contribute to the vulnerability of DA neurons [58], therefore, SZV558 by affecting multiple targets, may, through these differentiated mechanisms have a more favorable action than other MAO-B inhibitors as neuroprotective agent in the therapy of PD. The gene discussed is MAOB; the disease is Parkinson disease.